Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for Julie K Anderson�
8.50
+0.60 (7.59%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.96 - 8.51
52 week 5.40 - 17.72
Open 8.00
Vol / Avg. 529,616.00/1.40M
Mkt cap 531.07M
P/E     -
Div/yield     -
EPS -1.39
Shares 62.48M
Beta 0.00
Inst. own 46%
May 5, 2014
Q1 2014 Raptor Pharmaceutical Corp. Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Raptor Pharmaceutical Corp. Earnings Conference Call
Mar 13, 2014
Q4 2013 Raptor Pharmaceutical Corp. Earnings Release
Mar 4, 2014
Raptor Pharmaceutical Corp. at Cowen Health Care Conference
Feb 20, 2014
Raptor Pharmaceutical Corp. Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -261.65% -
Operating margin -135.76% -
EBITD margin - -
Return on average assets -68.01% -
Return on average equity -242.42% -
Employees 41 -
CDP Score - -

Address

SUITE 160, 5 HAMILTON LANDING
NOVATO, CA 94949
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company�s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms. As of August 31, 2010, the Company had no revenues. On September 29, 2009, the Company and its wholly owned subsidiary, ECP Acquisition, Inc., completed a reverse merger, business combination with RPC, pursuant to which RPC became its wholly owned subsidiary.

Officers and directors

Llew Keltner M.D., Ph.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Georgia L. Erbez Chief Financial Officer, Treasurer, Secretary
Age: 44
Bio & Compensation  - Reuters
Julie Anne Smith Chief Operating Officer, Executive Vice President - Strategy
Age: 41
Bio & Compensation  - Reuters
Kim R. Tsuchimoto Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Eric B. Mosbrooker Vice President - Health Services
Bio & Compensation  - Reuters
Paul K. Ross Vice President, Compliance Operations
Bio & Compensation  - Reuters
Thomas E. Daley Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Erich Sager Director
Age: 54
Bio & Compensation  - Reuters
Raymond W. Anderson Independent Director
Age: 70
Bio & Compensation  - Reuters